Hemofarm A.D.

Hemofarm A. D. is a Serbian pharmaceutical company specializing in a diverse range of prescription medications and consumer healthcare products, aimed at improving health outcomes across various markets. Founded in 1960 in Vrsac, Serbia, Hemofarm A.

D. is a pharmaceutical manufacturer focused on producing medications and healthcare products. The company, under the leadership of CEO Ronald Seeliger, has maintained its core business strategy without any major pivots. Hemofarm has engaged in 1 deal as of August 31, 2017.

Hemofarm specializes in the production and distribution of a diverse range of pharmaceutical products, primarily focusing on prescription medications, over-the-counter (OTC) drugs, and consumer healthcare (CHC) offerings. Their product portfolio addresses various health issues including chronic conditions, pain management, and health supplements. Hemofarm's products are targeted toward healthcare professionals, pharmacies, and end consumers across multiple geographical markets, including Southeast Europe, ensuring a broad distribution network that serves hospitals, pharmacies, and direct consumers seeking accessible healthcare solutions. Hemofarm generates revenue through a structured transaction model that includes both B2B and direct-to-consumer sales channels.

The company collaborates with healthcare providers and pharmacies to distribute its pharmaceutical products while marketing OTC and CHC products directly to consumers. Specific pricing plans are implemented for different product lines, which may vary based on category and distribution channel. Key products within their revenue-generating portfolio are essential medications that address common health concerns, contributing to stable revenue streams through a well-defined transactional framework. Hemofarm A.

D. aims to further its growth by designing and launching new products in upcoming years, with specific emphasis on enhancing its pharmaceutical offerings. The company is targeting expansion into select international markets by leveraging recent growth funding raised in August 2017 from Primer Capital. This funding is expected to bolster their capabilities in product development and market penetration, supporting their strategy to reach broader audiences and enhance product accessibility.